Benzinga | Nov 17, 2020 08:31AM EST

Morgan Stanley Initiates Coverage On Foghorn Therapeutics with Overweight Rating, Announces Price Target of $24

Morgan Stanley initiates coverage on Foghorn Therapeutics (NASDAQ:FHTX) with a Overweight rating and announces Price Target of $24.